Loading financials from SEC filings…
Drug manufacturers · Healthcare · Fiscal year ends Dec 31
Net income was −$42M.
Last 5 fiscal years
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 31.4 | 25.9 | 42.8 | – | – |
| Research & development | 66.7 | 53.0 | 8.8 | 8.2 | 22.8 |
| Operating income | −51.8 | −43.5 | −11.9 | −14.1 | −38.6 |
| Net interest incomeBanks | – | – | – | 0.6 | 2.6 |
| Interest expense | – | – | 0.0 | 0.4 | 0.0 |
| Pre-tax income | −45.7 | −33.3 | 18.7 | −17.4 | −41.7 |
| Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income | −45.7 | −33.3 | 18.7 | −17.4 | −41.7 |
| Diluted EPS | −0.71 | −0.45 | 2.17 | −7.83 | −3.71 |
| Diluted shares | 64.5 | – | 1.8 | 2.2 | 11.3 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | 118 | 38.6 | 7.4 | 83.6 | 58.0 |
| Receivables | 3.3 | 5.8 | 0.0 | 0.4 | 0.0 |
| Current assets | 128 | 73.4 | 7.5 | 88.2 | 59.0 |
| Net PP&E | 19.1 | 17.0 | 0.0 | – | – |
| Total assets | 154 | 95.5 | 7.5 | 88.2 | 59.6 |
| Payables | 8.6 | 4.2 | 0.9 | 4.6 | 4.6 |
| Deferred revenue | 25.1 | 20.8 | 0.0 | – | – |
| Current liabilities | 50.6 | 36.6 | 2.4 | 12.0 | 11.3 |
| Total liabilities | 103 | 67.6 | 11.4 | 25.6 | 31.6 |
| Shareholders' equity | 50.8 | −93.8 | −74.5 | 62.6 | 28.0 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating cash flow | −7.7 | −59.9 | −13.7 | −10.8 | −25.0 |
| Capital expenditure | 0.9 | 1.0 | 0.2 | – | – |
| Free cash flow | −8.6 | −61.0 | −13.9 | – | – |
| Depreciation & amortisation | 2.5 | 2.8 | 1.9 | – | – |
| Stock-based compensation | 5.2 | 4.4 | 0.6 | 0.8 | 6.4 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | −17.6% | 65.3% | – | – |
| EPS growth (YoY) | – | – | – | −460.8% | – |
| Operating margin | −165.0% | −167.8% | −27.7% | – | – |
| Net margin | −145.6% | −128.5% | 43.7% | – | – |
| Return on equityBlank when equity is negative | −90.1% | – | – | −27.8% | −149.1% |
| ROCEEBIT ÷ (assets − current liabilities) | −50.3% | −73.8% | −228.8% | −18.5% | −80.1% |
| Free cash flow margin | −27.4% | −235.4% | −32.4% | – | – |
| Cash conversion (CFO ÷ net income) | 0.17x | 1.80x | −0.73x | 0.62x | 0.60x |
| Receivable days | 38 | 82 | 0 | – | – |
| Interest cover | – | – | – | −32.8x | – |
| Current ratio | 2.52x | 2.01x | 3.20x | 7.33x | 5.20x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.